


1. -22. (Canceled)

23. (Currently Amended) A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has the following structure:



wherein:

X=a bond,  $(CH_2)_n$ , O, S, or  $O(CH_2)_n$ , O, or  $O(CH_2)_n$ ,

wherein  $n=1-6$ ;

$R_1=C_{1-6}$  alkyl, optionally substituted with OH or  $NH_2$ ;


$R_2=F$  or  $COOR_5$ ,

wherein  $R_5$  is  $C_{1-6}$  alkyl, optionally substituted with OH or  $NH_2$ ;

$R_3=CH_3$  or  $(CH_2)_n-COOR_6$ ,

wherein  $n=1-6$  and  $R_6$  is  $C_{1-6}$  alkyl, optionally substituted with OH or  $NH_2$ ;

$R_4=(CH_2)_n-COR_7R_8$ ,  $(CH_2)_n-R_{10}R_{11}$  or



$R_7=O$ ,  $NH$ , or  $NR_9$ ,

$R_8$ =optionally substituted aryl or heterocycle,

$R_9=C_{4-6}$  alkyl,

$R_{10}=O$ , S,  $SO$ ,  $SO_2$ ,  $NH$ , or  $NR_{12}$ ,

$R_{11}$ =aryl or heterocyclyl optionally substituted with  $(CH_2)_nCOOR_{14}$ ,

$R_{12}=C_{4-6}$  alkyl, optionally substituted with OH or  $NH_2$ ,

$R_{13}=C_{4-6}$  alkyl, optionally substituted with OH or  $NH_2$ ,


$R_{14}=C_{4-6}$  alkyl, optionally substituted with OH or  $NH_2$ ,

$R_{15}=(CH_2)_nCOOR_{16}$ ,

$R_{16}=C_{1-6}$  alkyl, optionally substituted with OH or  $NH_2$ , and


$R_{17}$ =not present or  $\text{COOR}_{18}$  wherein  $R_{18}$  is  $\text{C}_{1-6}$  alkyl, optionally substituted with OH or  $\text{NH}_2$ , and wherein  $n=1-6$ .

24. (Currently Amended) A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has a formula selected from the group consisting of:




X=bond,  $\text{CH}_2$ , or  $\text{OCH}_2$

R=lower alkyl optionally substituted OH or  $\text{NH}_2$ ;




R=lower alkyl optionally substituted by OH or  $\text{NH}_2$ ;




$n=1$  to  $3$

R=lower alkyl optionally substituted by OH or  $\text{NH}_2$ ;




$n=1$  to  $3$

R=lower alkyl optionally substituted by OH or NH<sub>2</sub>; and




R=lower alkyl optionally substituted by OH or NH<sub>2</sub>. ~~NH<sub>2</sub>~~



~~n=1 to 3 X=O, NH, NR where R is lower alkyl~~

~~Y=optionally substituted aryl or heterocyclyl; and~~




~~n=0 to 2~~

~~X=O, S, SO, SO<sub>2</sub>, NH NR or N(CH<sub>2</sub>)<sub>m</sub>COOH where m is 0 or 2~~

~~Y=aryl or heterocyclyl substituted with (CH<sub>2</sub>)<sub>m</sub>COOH where m is 0 to 2.~~


25. (Original) The compound, according to claim 24, wherein said compound has the following structure:



X=bond, CH<sub>2</sub>, or OCH<sub>2</sub>


R=lower alkyl optionally substituted OH or NH<sub>2</sub>.

26. (Original) The compound, according to claim 24, wherein said compound has the following structure:



R=lower alkyl optionally substituted by OH or NH<sub>2</sub>.


27. (Original) The compound, according to claim 24, wherein said compound has the following structure:



n=1 to 3

R=lower alkyl optionally substituted by OH or NH<sub>2</sub>.


28. (Original) The compound, according to claim 24, wherein said compound has the following structure:



n=1 to 3

R=lower alkyl optionally substituted by OH or NH<sub>2</sub>.

29. (Original) The compound, according to claim 24, wherein said compound has the following structure:




R=lower alkyl optionally substituted by OH or NH<sub>2</sub>.

30. – 31. (Canceled)

32. (Previously Presented) The method, according to claim 23, wherein the patient is a human.

33. (Previously Presented) The method, according to claim 23, wherein said method is used to treat a condition selected from the group consisting of hypertension, angina, ischemia, arrhythmia, congestive heart failure, and cardiac insufficiency.

34. (Currently Amended) A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has the following structure:



wherein:

X=a bond, (CH<sub>2</sub>)<sub>n</sub>, O, S, or ~~O(CH<sub>2</sub>)<sub>n</sub>~~, O, or O(CH<sub>2</sub>)<sub>n</sub>,

wherein n=1-6;

R<sub>1</sub>=C<sub>1-6</sub> alkyl, optionally substituted with OH or NH<sub>2</sub>;


R<sub>2</sub>=F or COOR<sub>5</sub>,

wherein R<sub>5</sub> is C<sub>1-6</sub> alkyl, optionally substituted with OH or NH<sub>2</sub>;

R<sub>3</sub>=CH<sub>3</sub> or (CH<sub>2</sub>)<sub>n</sub>--COOR<sub>6</sub>,

wherein n=1-6 and R<sub>6</sub> is C<sub>1-6</sub> alkyl, optionally substituted with OH or NH<sub>2</sub>;

R<sub>4</sub>=(CH<sub>2</sub>)<sub>n</sub>--COR<sub>7</sub>, R<sub>4</sub>=(CH<sub>2</sub>)<sub>n</sub>--R<sub>10</sub>, R<sub>4</sub> or



~~$R_7 = O, NH, \text{ or } NR_9,$~~

~~$R_8 = \text{optionally substituted aryl or heterocycle},$~~

~~$R_9 = C_{4-6}\text{-alkyl},$~~

~~$R_{10} = O, S, SO, SO_2, NH, \text{ or } NR_{12},$~~

~~$R_{11} = \text{aryl or heterocyclyl optionally substituted with } (CH_2)_n COOR_{14},$~~

~~$R_{12} = C_{4-6}\text{-alkyl, optionally substituted with OH or } NH_2,$~~

~~$R_{13} = C_{4-6}\text{-alkyl, optionally substituted with OH or } NH_2,$~~

~~$R_{14} = C_{4-6}\text{-alkyl, optionally substituted with OH or } NH_2,$~~

~~$R_{15} = \text{is H},$~~

~~$R_{17} = \text{not present or } COOR_{18} \text{ wherein } R_{18} \text{ is } C_{1-6} \text{ alkyl, optionally substituted with OH or } NH_2, \text{ and}$   
~~wherein  $n=1-6$ .  $n=1-6$ ;~~~~

~~provided that when  $R_2$  is fluoro; X is O;  $R_3$  is methyl,  $(CH_2)_{0-4}$  OR  $R_4$  is  $(CH_2)_n O C_{4-6}\text{-alkyl};$~~

